Bernstein brings significant healthcare investment, financial and public company Board expertise to Parexel

Parexel announced the appointment of Jeff Bernstein, Partner, Private Equity, Goldman Sachs Asset Management, and Co-Head, Goldman Sachs Healthcare Private Equity Investing, to its Board of Directors effective March 5, 2025. Bernstein succeeds Michael Bruun, Partner, Global Co-Head of Private Equity, Goldman Sachs Asset Management, as part of a planned rotation.
 
“Bruun has been a tremendous asset to our Board over the past two years. We’re incredibly grateful for his engagement, guidance and leadership,” said Peyton Howell, Chief Executive Officer. “
 
Bernstein brings significant healthcare investment, financial and public company Board expertise to Parexel. He joined Goldman Sachs as an Analyst in 2008, was named Managing Director in 2019 and made Partner in 2024.
 
Sheri McCoy, Chairperson of the Board, added, “Jeff’s extensive background in healthcare will be a great asset to the Board as we prepare for the next phase of Parexel’s growth. We look forward to leveraging his insights as we work to advance our strategic roadmap and deliver on our growth objectives."
 
"I’m pleased to join Parexel’s Board," said Mr. Bernstein. "I look forward to supporting the company as it differentiates and innovates to advance its position as a leading global CRO  and accelerate the delivery of life-enhancing new therapies to patients worldwide.”